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Abstract
Background: Apathy in patients with epilepsy is associated with a wide range of consequences that reduce the
patient’s ability to perform social functions and participate in self-care and rehabilitation programs. Therefore,
apathy is one of the important diagnoses of the healthcare team in the process of caring for epileptic patients and
its dimensions need to be examined and recognized. Therefore, appropriate instruments with the sociocultural
milieu of each community should be provided to health care providers. The aim of the present study was to design
and measure epilepsy–related apathy scale (E-RAS) in adults with epilepsy.
Methods: This study of sequential exploratory mixed methods design was conducted in Iran from April 2019 to
December 2019. In the Item generation stage, two inductive (face-to-face and semi-structured interviews with 17
adult epileptic patients) and deductive (literature review) were used. In item reduction, integration of qualitative
and literature reviews and scale evaluation were accomplished. For Scale Evaluation, face, content, construct
[exploratory factor analysis (EFA) (n = 360) and confirmatory factor analysis (CFA) (n = 200)], convergent and
divergent Validity and reliability (internal consistency and stability) were investigated.
Results: The results of EFA showed that E-RAS has four factors, namely, motivation; self-regulatory; cognition and
emotional-effective. These four latent factors accounted for a total of 48.351% of the total variance in the E-RAS
construct. The results of CFA showed that the 4-factor model of E-RAS has the highest fit with the data. The results
of convergent and divergent validity showed that the values of composite reliability (CR) and average variance
extracted (AVE) for the four factors were greater than 0.7 and 0.5, respectively, and the value of AVE for each factor
was greater than CR. The Cronbach’s alpha coefficient for the whole scale was obtained 0.815. The results of the
test-retest showed that there was a significant agreement between the test and retest scores (P < 0.001).
Conclusion: E-RAS is a multidimensional construct consisting of 24 items, and has acceptable validity and reliability
for the study of epilepsy-related apathy in adult epileptic patients.
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Highlights
 Epilepsy in adults is associated with several
problems due to its chronic nature and symptoms
such as seizures and social stigma.
 Disease-related problems may affect the patient’s
understanding, feeling, and behaviour toward the
disease and lead to behavioural symptoms in the
patient.
 Apathy in patients with epilepsy can have a wide
range of consequences and should be investigated
and identified.
 To gain information on epilepsy-related apathy, ap-
propriate instruments with the socio-cultural milieu
of each community are needed.
 The E-RAS is a valid and reliable instrument for
assessing the motivation; self-regulatory; cognition
and emotional-effective dimensions of the apathy in
adults with epilepsy.
Background
Neurological disorders are one of the chronic diseases
that are commonly associated with apathy. In the litera-
ture review, 20–80% of patients with Parkinson’s disease,
progressive supranuclear palsy, stroke [1] and Alzhei-
mer’s disease [2] were reported to have epilepsy. Apathy
in patients with chronic diseases can reduce treatment
response due to reduced adherence to the treatment
protocol [3]. Therefore (For this reason), apathy due to
cognitive and emotional problems associated with the
disease in chronic disease patients (in patients with
chronic diseases) has currently been emphasized [4].
Epilepsy is a chronic non-communicable brain disease
that affects about 50 million people worldwide and
therefore accounts for one of the leading neurological
diseases across the world. The incidence rate of epilepsy
is reported to be 61.4 per 100,000 population every year
(95% CI; 50.7–74.4) [5]. The prevalence of epilepsy in
Iran is reported to be 5% (95% CI: 2–8) [6]. Self-care be-
haviors are the basis for treating and controlling seizures
that can be affected by apathy [7]. Although apathy can
be a personality trait, suffering from a chronic illness
may lead to the disease-related apathy due to long-term
involvement with it and its treatment process. Apathy
refers to a set of behavioural, emotional, and cognitive
traits such as decreased interest in daily activities, lack of
motivation to engage in creative activities, a tendency to
withdraw early from activities, lack of interest, and di-
minished emotions [8] various definitions and character-
istics have been provided for the concept of apathy.
Some define indifference as a lack of motivation related
to the patient’s level of performance in terms of age and
culture, provided that lack of motivation in apathy is not
due to decreased level of consciousness, cognitive im-
pairment, emotional distress, or direct physiological ef-
fects of the use of substances such as drugs or
medications [9].
Other researchers have referred to apathy as the failure
to respond to stimuli in the form of inaction. Others
consider apathy to be a disorder in the dimensions of ex-
ecutive cognition or will (i.e., a decrease in human
power, potency, or ability to initiate action, or a low de-
sire for goal formulation and voluntary behavior) [10,
11]. In clinical settings, apathy is diagnosed by decreased
vitality, decreased self motivation and poor initiative [8],
lack of interest in learning new things or new experi-
ences, and decreased emotional response to effective
changes in the course of treatment or failure to respond
to positive or negative events [12]. According to Robert
et al. (2018), four indicators of apathy in patients with
brain disorders include 1- Reduced goal-directed behav-
iour compared to the patient’s previous level of perform-
ance, 2. Having two of the following three main
symptoms: Behavioral/cognitive symptoms (decreased
level of public activity, less persistence, decreased inter-
est, personal wellbeing), Emotional symptoms (verbal or
physical expressions, impact on others, emotional reac-
tions to the environment, less spontaneous emotions,
empathy) and Social symptoms (spontaneous social ini-
tiative, environmentally stimulated social interaction, re-
lationship with family members, verbal interaction,
homebound) for at least 4 weeks and continuously. 3-
Clinically, the first and second indicators lead to disrup-
tion in personal, social, occupational, or other important
areas of functioning and 4 - Lack of simultaneity of the
first and second indicators with other clinical disorders
such as physical disabilities, motor disabilities, substance
use or environmental changes [13].
Apathy in patients with chronic disease is associated
with a wide range of consequences; for example, it can
cause the patient not to strive for daily activities and be-
come dependent on others or it can reduce the patient’s
quality of life [14]. Apathy increases the care burden of
family caregivers [15] and reduces the patient’s ability to
perform social functions and participate in self-care and
rehabilitation programs [12]; the patient’s care-related
needs including physical, mental and social care increase
as well [2].
Because apathy is challenging to diagnose due to its
similar characteristics to depression and requires its own
diagnostic instruments [8], and apathy treatment is often
complicated and difficult, and the available guidelines
for therapists (clinical psychologists) are limited, it is ne-
cessary to take preventive measures to identify the fac-
tors effective on the treatment process and improve the
outcomes of treatment. Apathy is one of the important
diagnoses of the healthcare team in caring for epileptic
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patients, and therefore should be examined and charac-
terized [12, 16, 17]. For this purpose, appropriate instru-
ments with each community’s socio-cultural milieu
should be provided to healthcare providers [17]. The
available instruments (Table 1) often measure general-
ized apathy in living with illness or in healthy conditions,
and none of them examine the patient’s specific feelings,
thoughts, and behaviors in facing chronic illness.
Although Geun Seo Jong et al. (2017) used the AES-Self
(AES-S)-Self (AES-S) version of Marin’s apathy evalu-
ation scale (AES) to examine the apathy in epileptic pa-
tients [12], the AVS does not explicitly examine the
apathy related to different aspects of epilepsy. Marin
et al. (1991) argue that epilepsy in different groups is
under environmental, psychological and social influences
that need to be investigated under the same conditions
Table 1 Available instruments for assessment of apathy
NO Authors Scale Title Item
Number
Domain Target group Type





2 Kay et al.(1989) [19] Positive and Negative
Symptoms scale
8 schizophrenia Sub-scale
3 Andreasen(1989) [20] Assessment of Negative
Symptoms
8 schizophrenia Sub-scale
4 Burns etal(1990) [21] Apathy 5 Single factor Huntington and
Alzheimer disease
full
5 Marin etal(1991) [22] Apathy Evaluation
Scale (AES)







6 Cummings et al.(1994) [23] Neuropsychiatric
Inventory
9 dementia patients Sub-scale
7 Starkstein et al.(1995) [24] Apathy Scale 14 Single factor Alzheimer’s disease full
8 Grace et al.(1999) [25] Frontal Systems
Behaviour scale
27 frontal lobe brain-
damaged patients
Sub-scale
9 Strauss and Sperry(2002) [26] Dementia Apathy
Interview and Rating
16 Alzheimer Disease Sub-scale




20 All groups Sub-scale
11 Robert et al.(2002) [28] Apathy Inventory 3 Emotional blunting,








12 Belanger et al.(2002) [29] Key Behavior Change
Inventory
28 Elderly with memory
disorder
Sub-scale
13 Sockeel etal(2006) [30] The Lille apathy rating
scale (LARS)
33 reduction in everyday
productivity; lack of





concern; poor social life
and extinction of self-
awareness
Parkinson’s disease full












15 Ang etal(2017) [32] Apathy Motivation Index 18 behavioral, social
and emotional
All groups full
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[22]. Because social stigma and chronic nature of epi-
lepsy and its symptoms such as seizures may affect the
patient’s feelings, reactions, and behaviour in dealing
with the disease and its treatment [33], it is necessary to
have a specific instrument assessing apathy in epileptic
patients. Collins et al. (2006) emphasized the necessity
and appropriateness of using mixed methods to assess
existing instruments’ appropriateness or utility [34].
Therefore, this study was conducted to design and psy-
chometrically analyze epilepsy-related apathy scale (E-
RAS) in adults with epilepsy.
Methods
Design and setting
This study of sequential exploratory mixed methods de-
sign was conducted in Iran from April 2019 to Decem-
ber 2019.This study is part of a research project entitled
“ relationship between disease– related fear with apathy
and nutrition status in adults with epilepsy: a multiple-
center study(Cod; IR.MUBABOL.HRI.REC.1398.132)”.
Creswell and Plano Clark (2011) recommended using se-
quential mixed methods research design for scale devel-
opment and exploratory instrument design. Sequential
mixed methods research design consists of three phases:
a qualitative phase to define the construct of the instru-
ment; an instrument development phase including item
generation and revision; and a confirmatory quantitative
phase for instrument testing [35]. Hinkin et al. (1995)
proposed three phases: item development, scale develop-
ment, and scale evaluation, to create a rigorous scale
[36]. The present study was also conducted in three
phases.
Item generation
The item generation step is also called question develop-
ment. Two methods, i.e., inductive and deductive, are
used to identify appropriate items [36].
First phase
In this phase, the inductive method was used. The
method is also known as grouping or classification
from below. In this phase, the items are generated
from qualitative data from direct observations and in-
dividual interviews or focus groups, including the
target-population [37].
Data collection
The research settings were the Iranian Epilepsy Associ-
ation and the neurological clinics of the hospitals affili-
ated to Iran University of Medical Sciences, and the
office of neurologists in the cities of north Iran. In this
phase, sampling was purposeful. Inclusion criteria in-
cluded having suffered from epilepsy for at least 1 year,
depressive disorder (obtaining a score of 4 or less from
the short form of the Beck’s Depression Inventory ([38],
treatment with antiepileptic drugs for at least 1 year, age
of 74–18 years and lack of substance abuse. Exclusion
criteria included unwillingness to continue participation
in the study. Participants were people who could provide
first-hand information to the researcher (young patients
with epilepsy). Sampling continued until data saturation
was achieved. Data saturation in qualitative research is
obtained when the data are duplicated, and no new code
is obtained [39]. Finally, 17 semi-structured face-to-face
interviews were performed. Individual interviews lasted
40min on average. Participants were asked the following
questions:
1. Please explain to me the concept of epilepsy-related
apathy.
In addition, during the interviews, what are the prob-
ing questions such as “what do you mean?”, “If possible,
please explain more?” or “How did you feel about that?”
were also raised.
At the completion of each interview, participants were
asked to state something if they felt it as having not
talked of throughout the interview and then the inter-
viewer spoke of the possibility of further interviews. The
interviews were conducted in the researcher’s room at
the request of the participants.
Trustworthiness of data
In this study, Guba and Lincoln’s four criteria, i.e., cred-
ibility, dependability, confirmability, and transferability,
were used to ensure the qualitative phase’s accuracy and
precision [40]. To obtain valid data, member checking
was used to verify the accuracy of the extracted data and
codes. Codes that did not reflect the views of the partici-
pants were modified. In order to conduct peer checking,
the texts of some of the interviews and extracted codes
and categories were reviewed by three faculty members
in addition to the authors, with 93–95% agreement
among the results. The method proposed by Paulite and
Hangler was used to calculate the agreement [41]. In
order to investigate the transferability, the findings were
shared with some patients with epilepsy who did not
participate in the study, and they confirmed the appro-
priateness of the findings with their experiences. Max-
imum variation sampling in terms of age, sex, education
level, marital status, age at onset of epilepsy, duration of
of epilepsy, seizure frequency per month, and duration
of administered antiepileptic drugs (AEDs) intake was
observed.
Data analysis
Data analysis was performed using conventional content
analysis method based on Graneheim and Lundman
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method [42]. For this purpose, first, the data were read
line by line, and the open codes (which are the words of
the participants themselves) were extracted. The ob-
tained codes were compared with previous codes and
codes that were conceptually similar were assigned to
the same category. Gradually, categories were formed.
The categories were also compared and merged with
each other as needed, or in some cases, one category
was divided into two or more categories, or a code was
transferred from one category to another. Eventually, the
main subcategories were formed. In this study,
MAXQDA/10 software was used to organize and
categorize the extracted codes.
Second phase
In this phase, the deductive method was used. The avail-
able literature and scales were reviewed and evaluated.
The deductive method is also known as logical partition-
ing or classification from above [43]. In this phase, the
literature review was conducted in Pubmed, Scopus,
Web of Science and PsycINFO databases using the key-
words fear, apathy, epilepsy-related apathy, adult scale,
questionnaire, and epilepsy from 10th April until 1st
June 2019. In total, 30 relevant articles were retrieved
that had been published from 1962 to 2019. Some of the
articles addressed the tools that measured apathy (Table
1), and some were qualitative studies on the concept of
apathy and its dimensions.
Item reduction
Third phase
Integration of qualitative and literature reviews: provid-
ing the pool of items. First, each interview was coded,
and similar codes merged into categories and subcat-
egories. Then all the texts, including the available tools,
qualitative studies related to the studied construct were
coded separately, and then the same codes were formed
the categories and subcategories. The codes and
categories extracted from each phase of the study were
examined separately. Then all the codes and categories
of both phases were put together. Duplicate items were
deleted, and similar items merged. Because the codes
and subcategories were the basis for building items pool,
they were rated more deliberately. They were coded,
classified, and labelled over 3 months until the research
team reached a consensus. In this part of the study,
using the information obtained in the qualitative stage
(interviews), a pool of 29 items was formed. An example
of the items pool formation process is presented in
Table 2. In the deductive stage (literature review), 15
items were obtained and added to the items pool formed
in the qualitative stage. The items were re-checked by
the research team, the duplicate items were deleted, and
similar items were merged. Some items were also modi-
fied. The items were edited to be suitable for both low
and medium literacy levels. E-RAS was finally included
in 31 items for adults with epilepsy.
Scale evaluation
In examining the validity of a research tool, face validity,
content validity, and construct validity need to be evalu-
ated [44].
Face validity
The face validity of E-RAS was investigated in two quan-
titative and qualitative ways:
Qualitative face validity
Ten adult patients with epilepsy were asked to comment
on each statement’s level of difficulty, appropriateness,
and ambiguity. Corrective comments were applied to the
instrument. The time required to respond to the tool
was also estimated.
Table 2 An example of the process of determining the spheres designed from participants’ experiences
Item Category Participants’ experiences
Criticizing and rejecting me by others reduces
my motivation to treat my illness.
Motivation I remember going to school. The time I was 15 years old. My
friends didn’t let me join their circles. They rejected me. But I
hoped I would be cured and my illness would be controlled. I
did not lose my spirit. I had motivation for the future of my life.
I actively follow behaviors related to the dimensions of
controlling my illness (such as preventing possible injuries
during seizures and adhering to the therapeutic regimen).
Self-Regulatory It is important for me to try to follow what my doctor tells me.
I don’t ride a bicycle and I care not to get injured during a seizure.
Cooperation of others, I will explain the conditions/
symptoms of my illness to them.
Cognition When I meet someone like new colleagues or friends who do not
know my condition, I tell them about the disease and its symptoms.
I ask them to understand me and help me during the seizure.
Deprivation of social rights due to my illness has made
me angry and frustrated me in continuing my social
activities.
Emotional- Effective I have long been looking for a job, but as soon as the employer
understands that I have epilepsy, he doesn’t give me the job. I wanted
to marry my favorite girl, but my illness prevented her family from
agreeing. I’m nervous and desperate to do something.
Shamsalinia et al. BMC Neurology          (2021) 21:121 Page 5 of 17
Quantitative face validity
The E-RAS face validity was quantified using the Item
Impact method. For this purpose, for each of the tool-
bars, a 5-part Likert scale (perfectly important = 5, im-
portant = 4, moderately important = 3, slightly
important = 2 and not at all important = 1) was consid-
ered. Then, using the Item Impact method formula, the
quantitative face validity was calculated.
ðImportance %ð Þ  Frequency ¼ Item Impact Score
A score higher than 1.5 was considered acceptable for
each item [45].
Content validity
Two qualitative and quantitative methods are used to
determine the content validity of designed tools [46]. In
this study, the content validity of E-RAS was evaluated
by two methods: qualitative and quantitative:
Qualitative content validity
The qualitative content validity of E-RAS was evaluated
by ten experts (5 Nursing PhD holders, two psycholo-
gists, two neurologists and three geriatricians). These in-
dividuals were asked to comment on the observance of
the grammar, the use of appropriate words, the place-
ment of the items in their proper place, and the appro-
priate scoring of the questionnaire [47]. In this study,
Content Validity Ratio (CVR) and Content Validity
Index (CVI) were measured to quantify the content
validity:
CVR Lawshe’s model (1975) was used to calculate the
CVR [48]. In this way, the questionnaire was given to 10
people (the same people who were invited to collaborate
to check the validity of quality content), and they were
asked to comment on the necessity of tool items using
the 3-point Likert scale (Unnecessary = 1, Useful but un-
necessary = 2 and Necessary = 3). The CVR was then cal-
culated using the following formula.
CVR ¼ ne - N=2ð Þ
N 2
 
CVR ¼ ne - N=2ð Þ
N 2
 
The minimum acceptable value for CVR according to
the views of 10 experts is 0.62 [49].
CVI To calculate the CVI, the designed tool was
given to 10 professionals (the same people who were
invited to collaborate to review the CVR tool) to cal-
culate each item based on the Waltz and Basel con-
tent index (52) in terms of relevance to a 4-point
Likert scale (Irrelevant = 1, Needing major revision = 2,
Relevant yet needing revision = 3, and Absolutely




where ni represents the number of experts that scored
the item as 3 or 4; and n represents the total number of
experts panel members.
Construct validity
Then the mean CVI was calculated for all tool items; the
acceptable value for CVI is equal to and higher than
0.78 [49, 50]. The validity of the structure was assessed
using exploratory factor analysis (EFA; N = 360) and
confirmatory factor analysis (CFA; N = 200).
EFA The internal correlation of the instrument should
be examined before sampling for construct validity in-
vestigation. A pilot study was conducted to calculate it.
After confirming the items’ internal correlation, explora-
tory factor analysis was performed to determine whether
the tool is a single scale or consists of several domains.
Then, confirmatory factor analysis was performed to
confirm the extracted dimensions [51]. Before the EFA,
360 adult patients with epilepsy were enrolled in the
study using the Convenience Sampling method. The in-
clusion and exclusion criteria of the study were the same
as those mentioned in the qualitative phase. For this
purpose, a cross-sectional study was performed.
To extract latent factors, exploratory factor analysis
was performed using the principal axis factoring (PAF),
Varimax rotation, and scree diagram. Eigenvalue was
used more than once to determine the number of the
factors extracted [52]. The Kaiser-Meyer-Olkin (KMO)
index was used to assess sampling sufficiency, and the
Bartlett’s test of sphericity was used to investigate the
appropriateness of the factor analysis model. KMO
values between 0.7 and 0.8 are considered acceptable,
and values between 0.8 and 0.9 excellent [53].
The presence of one item in the factor was determined




n − 2ð Þ
p
In this formula, CV is the number of factors that can
be extracted and n the sample size of the study [54].
CFA The factors extracted using the first- and second-
order CFA (maximum likelihood estimation) and the
most common goodness-of-fit indices of modeling
structural equation were examined. The number of
samples in the confirmatory factor analysis was 200
people. Fit indices used in the study include: Chi-
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square (χ2), Chi-square/degree-of-freedom ratio (nor-
malized Chi-square CMIN/DF), Adjusted Goodness-
of-Fit Index (AGFI) > 0.8, Parsimonious Comparative
Fit Index (PCFI) > 0.50, Comparative Fit Index
(CFI) > 0.90, Incremental Fit Index (IFI) > 0.90, Parsi-
monious Normed Fit Index (PNFI) > 0.50 and Root
Mean Square Error of Approximation (RMSEA) <
0.05 good [55]. In the second-order CFA, it was as-
sumed that the extracted latent factors were present
in the first-order CFA. Therefore, the second-order
CFA, more general concepts at the secondary and
higher levels will present. Moreover, the construct
validity was investigated through correlations be-
tween the construct factors and demographic and
clinical variables.
Convergent and divergent validity
The convergent and divergent validity of the D-RAS
were evaluated based on the Fornell and Larker (1981)
approach using Average Variance Extracted (AVE),
Maximum Shared Squared Variance (MSV), Average
Shared Square Variance (ASV) and Composite Reliability
(CR) [56]. Acceptable indicators for convergent validity
are AVE > 0.5 and for divergent validity are MSV < AVE
and ASV < AVE [57].
Reliability
In the reliability study, three characteristics internal
consistency, stability and error measurement were
evaluated:
Internal consistency
Internal consistency refers to the homogeneity of vari-
ables within a tool and, in fact, an estimate of the correl-
ation between the variables that make up the structure
or tool [58]. In this study, the coefficients of Cronbach’s
alpha coefficient, McDonald’s Omega and Theta (θ)
were estimated and values greater than 0.7 were
accepted [59]. Then, the CR was calculated using con-
firmatory factor analysis. By replacing Cronbach’s alpha
coefficient in structural equation modelling, we can
calculate the construct reliability. The construct reliabil-
ity can be calculated based on the composite reliability
and the Average Variance Extracted (AVE). Construct
reliability should fulfil CR > 0.7 and AVE > 0.5 [60].
Stability
The D-RAS was administered twice with a two-week
interval to 50 adults with epilepsy who fulfilled the cri-
teria to enter the study. Pearson correlation coefficient
and Intraclass Coefficient Correlation (ICC) correlation
coefficient were then calculated. The ICC of 0.8 or
higher indicates acceptable stability [61]. During the
test-retest, the amount and management of the missing
values were taken into account. Another point that was
considered was the samples’ stability in the test-retest
interval in terms of the characteristic in question. In case
of any mental, psychological or severe stress, the sample
was excluded from the second phase.
Standard error of measurement (SEM)
SEM is one of the indices of measurement accuracy and
test reliability. Due to the error in repeating each meas-
urement, there is always some difference [62]. In the
present study, the standard error measurement ( SEM
¼ SD  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1 − ICCp  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1 − ICCp ) and the minimally
detectable change (MDC ¼ SEM Z score  ffiffiffi2p  Z
score  ffiffiffi2p ) and the minimally important change
(MIC = 0.5 × SD ofΔscore × SD ofΔscore) were
calculated.
Ceiling effect and floor effect
This effect occurs when more than 15% of the respon-
dents score the highest or lowest attainable score [51].
Scale scoring
In this instrument, the Likert scale was used for
responding to the items. In the final version of the ques-
tionnaire, standardization 100 method was used to score
and compare the scores of different subscales of the
questionnaire. The following linear transformation for-
mula was used to convert the scores of the subscales
and the whole questionnaire to a score of 0 to 100 [63].
transformed score ¼ actual raw score − lowest possible raw score
possible raw score range
 100
The normal distribution of data, outliers and missing data
In order to determine whether data distribution is nor-
mal or not, skewness and kurtosis indices should be cal-
culated. The assumption of normality was investigated
on the basis of skewness at ±3 and kurtosis at ±7 [64].
Mardia coefficient (8>) was used to check the normality
of multivariate normality [65]. To investigate the lack of
multivariate outlier data, the d-squared Mahalanobis
index (above 20) was examined (P < 0.001) [66]. The per-
centage of missing data was evaluated using Multiple
Imputation and then replaced by the average respondent
response [57].
Data analysis
For EFA, SPSS 24 software was used, and for CFA,
AMOS24 software, and for other calculations, EXCEL
2016 software was used. JASP software was also used in
this study to calculate the Omega McDonald’s coeffi-
cient. Depending on the type of variable, Pearson’s cor-
relation coefficient or point-biserial and polyserial
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correlation coefficients were used to investigate the cor-
relation between factors and demographic and clinical
variables.
Results
The demographic characteristics of the study partici-
pants are presented in Table 3.
In the qualitative section of the face validity investiga-
tion, the item I disagree with most of the suggestions of
my treatment team was deleted. In the quantitative sec-
tion of the face validity investigation, two items: Looking
at my job or education is important to me to the end
and I have the initiative were deleted due to score of less
than 1.5. Therefore, in this section, the 31-item scale
was reduced to a 28-item scale. In the qualitative study
of content validity, two items were modified, and all the
proposed changes of experts were made to the appear-
ance of items. The quantitative study of content validity
was performed by CVR and CVI, with one item “I’m
concerned about my illness” was deleted due to a CVR
of less than 0.62 and one item “I don’t care about com-
municating with the treatment team” due to a CVI of
less than 0. 78. Finally, a 26-item scale remained to be
investigated for its construct validity. The results also
showed that KMO obtained 0.728 and Bartlett’s test ob-
tained 3154,373 (P < 0.001). The scree diagram (Fig. 1)
shows that four factors were extracted from the explora-
tory factor analysis of the E-RAS construct. These four
latent factors accounted for 3.632, 3.162, 2.866, and
1.944 of the Eigenvalue, respectively, collectively explain-
ing 48,351% of the total variance in the E-RAS construct.
The results of the exploratory factor analysis showed
that the two items Although I’m sick, I’m neither happy
nor sad (I’m something in the middle) and Worrying
about my illness has overshadowed my emotional reac-
tions were deleted because of having a factor load of less
than 0.4 (Table 4).
In the first-order factor analysis, the goodness of fit
index (chi-square) was obtained 577.195 (P < 0.001)
(241) χ2. Then, to evaluate the fit of the model, other in-
dicators were examined that all indicators RMSEA =
0.075, PCFI = 0.64, PNFI = 0.68, AGFI = 0.70, IFI = 0.92
and CFI = 0.91 confirmed the appropriate fit of the final
model (Table 5 and Fig. 2). After study of the first-order
confirmatory factor analysis, the E-RAS structural com-
ponents were separately investigated for correlation be-
tween the structures and the subscales were identified
using the structural equation model to measure whether
the number of components is incorporated into the gen-
eral E-RAS concept, The second-order factor analysis
was also performed. The fit indices of this confirmatory
factor analysis are shown in Table 5 in comparison with
those of the first-order confirmatory factor analysis. Fig-
ure 3 illustrates the structural model and confirmatory
Table 3 Socio-demographic and clinical profiles of the







Under high school diploma 265 47.3
High school diploma 187 33.4














Approximately sufficient 214 38.2









< 19 24 4.3
19–21 68 12.1
22–23 203 36.3
> 23 265 47.3
Age: mean (SD), Years 38.83 (11.78)
Age at onset of epilepsy: mean (SD), years 7.97 (7.58)
Seizure frequency: mean (SD), month 2.53 (2.55)
Duration of epilepsy: mean (SD), years 30.70 (11.49)
Duration of administered antiepileptic
drugs (AEDs) intake: mean (SD), years
27.46 (11.45)
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factor analysis of the E-RAS construct with factor loads
with standardized coefficients. The values of the factor
load obtained for all E-RAS items were higher than 0.50
(P < 0.001).
The results show that epilepsy-related indifference in
all four factors had a significant relationship with the
demographic and clinical variables of adults with epi-
lepsy (Table 6).
The results also showed that, in the first-order con-
firmatory factor analysis, the AVE of all factors was
greater than 0.5 and the AVE of each factor was greater
than that of ASV and MSV. The results showed that the
E-RAS construct had convergent and divergent validity.
In the second factor analysis, AVE was obtained > 0.5,
which confirms the convergent validity (Table 7).
The results also showed that the internal stability and
CR (> 0.7) of the four extracted factors from the E-RAS
construct were confirmed (Table 7). The stability (test-
retest) of the scale was investigated using ICC. The
mean pre- and post-test scores were 64.46 ± 10.96 and
62.25 ± 6.48, respectively. The ICC was equal to 0.843
(P < 0.001, 95% CI: 0.773–0.900) (Table 8). The results
showed that the SEM, MDC and MIC of E-RAS were
4567, 12,660 and 5321, respectively (Table 8).
The results showed that more than 15% of the respon-
dents obtained the highest or lowest possible score on
E-RAS (Table 9).
Scale scoring
The final version of E-RAS consists of 24 items. Scale in-
cludes 4 dimensions including motivation (7 items); self-
regulatory (3 items); cognition (5 items) and emotional-
effective (9 items). The items are rated on a 4-part Likert
scale (Almost always = 4, Often = 3, Occasionally = 2,
Hardly Ever = 1). The items 17,18,19,20, 21, 23, 25 and
26) are scored inversely. The minimum and maximum
attainable scores on the scale are 45 and 91, respectively.
The responses to each subscale’s items are summed up,
and then calculated and expressed as percentage for
each subscale and the entire scale using the linear trans-
formation formula. Eventually a score of 0 to 100 is ob-
tained, with a lower score indicating less epilepsy related
apathy in an adult patient with epilepsy.The results
showed that the value of Mardia coefficient is 8.54 and
its critical ratio is 2.46. Therefore, it can be concluded
that the hypothesis of the multivariate normality with
proper approximation was fulfilled.
Discussion
This study investigated the reliability and validity of the
E-RAS, a new instrument for the assessment of apathy
in adults with epilepsy. Available tools such as dimen-
sional apathy scale measure apathy in healthy and nor-
mal samples [67] and other tools (Table 1) measure
general apathy in different target groups. Therefore, the
Fig. 1 Scree plot for the exploratory factor analysis of the E-RAS
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researchers preferred not to compare the psychometric
properties of E-RAS with other tools that measure ap-
athy. The present study was conducted with the aim of
designing and evaluating E-RAS by mixed method.
Recently, researchers have presented mixed methods as
the most appropriate method for validation. The use of
quantitative and qualitative methods for the generation
of items increases the validity of the content [68].
Table 4 Exploratory factor analysis of the E-RAS (N = 360)
Factor Name Items Factor
loading
ah2 Eigenvalues % of variance
Motivation 2. Despite having epilepsy, it’s easy for me to pursue
my interests/aspirations.
0.648 0.530 3.632 15.134
I’m interested in engaging in NGOs of epileptic patients. 0.609 0.424
21. To start any new therapeutic method or recommendation,
I need a force to motivate me.
0.424 0.391
17. Someone needs to listen to me every day about what
I can do to manage my illness.
0.594 0.475
9-I need energy to follow up my illness 0.553 0.609
3. Criticizing and rejecting me by others reduces my motivation
to treat my illness.
0.572 0.355
26. I’m not interested in participating in self-care programs. 0.592 0.384
Self-Regulatory I assess how to do health-promoting behaviors (such as
exercising, resting adequately, eating healthy foods, avoiding
alcohol, smoking and drugs, and avoiding stress).
0.662 0.547 3.162 13.174
10. I actively follow behaviors related to the dimensions of
controlling my illness (such as preventing possible injuries
during seizures and adhering to the therapeutic regimen).
0.618 0.574
5. I believe I can actively participate in decisions related to
disease management.
0.563 0.407
Cognition 11. I understand the importance of self-care. 0.595 0.638 2.866 11.940
13. I know that I have to follow my treatment protocol for
the rest of my life.
0.794 0.640
14. I understand the symptoms and consequences of my
illness (such as seizures, occupational, educational, and family
problems, and cognitive problems such as time, place, and
person, and memory problems).
0.785 0.650
16. I know I need to follow up my treatment on time and
not delay it.
0.484 0.536
15. To justify and attract the cooperation of others, I will
explain the conditions/symptoms of my illness to them.
0.488 0.373
Emotional- Effective 25. I don’t care how others communicate with me. 0.630 0.475 1.944 8.102
6. The new goals and plans I have for the future of my life;
are not overshadowed by my illness.
0.791 0.634
12. In controlling my illness, I accept the new methods
offered by the treatment team (such as brain surgery
and traditional medicine).
0.568 0.376
18. Deprivation of social rights due to my illness has
made me angry and frustrated me in continuing my
social activities.
0.515 0.376
19. The uncertainty about the future of my illness has made
precautions related to treatment unimportant to me.
0.657 0.501
23. I don’t get excited when I have positive treatment results. 0.645 0.437
4. Although I suffer from distress, I am interested in expressing
my feelings about my illness.
0.514 0.354
20. My fear of the symptoms of the disease has led me toward
feeling a kind of alienation.
0.653 0.585
7. I don’t care how others react to my symptoms. 0.594 0.534
ah2: Communalities
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Onwuegbuzie et al. (2010) also believe that mixed
methods can be used to provide content-related evi-
dence for face validity, item validity and sampling valid-
ity, and construct-related evidence for substantive
validity, outcome validity, and generalizability [69]. In
this study, inductive and deductive methods were used
to prepare items pool. When the purpose is to design a
new tool or develop a scale, the validity and reliability of
the item generation phase can be increased by using
qualitative and quantitative methods [35, 70]. In the
Fig. 2 Structure of E-RAS: modified model of first-order confirmation factor analysis
Table 5 Fit indices of the first- and second-order confirmatory factor analysis of the E-RAS
CFA χ2 df P-value CMIN/df RMSEA PCFI PNFI AGFI IFI CFI
First-order after structure modification 577.195 241 < 0.001 2.39 0.075 0.64 0.68 0.70 0.92 0.91
Second-order after structure modification 480.868 239 < 0.001 2.01 0.062 0.72 0.83 0.88 0.95 0.96
Abbreviations: E-RAS epilepsy– related apathy scale, CFA confirmatory factor analysis, CMIN/DF Chi-square/degree-of-freedom ratio, RMSEA Root Mean Square Error
of Approximation, PCFI Parsimonious Comparative Fit Index, PNFI Parsimonious Normed Fit Index, AGFI Adjusted Goodness-of-Fit Index, IFI Incremental Fit Index,
CFI Comparative Fit Index
Fit indices: PNFI, PCFI, AGFI (> 0.5), CFI, IFI (> 0.9), RMSEA (> 0.08), CMIN/DF (> 3 good, > 5 acceptable)
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Fig. 3 Structure of E-RAS: modified model of second-order confirmatory factor analysis




Motivation Self-regulatory Cognition Emotional-Effective
Age .252** .206** .145** .153**
Age at onset of epilepsy .160** −.132* −.108* .122*
Seizure frequency .173** −.129* −.147* −.161**
Level of education .154* .219** .118** .134**
Duration of AEDs intake .187** .277** .146** .129*
Genderb −.169** −.225** −.191** −.261**
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present study, after preparing the primary instrument, E-
RAS psychometric indicators were examined. Designing
or selecting research instruments requires special atten-
tion to psychometric criteria [71]. In this study, in order
to investigate the face validity of E-RAS, the opinions of
a number of patients with epilepsy were elicited. Target
population’s judgements are extremely important in
assessing face validity and can make the tool applicable
to the target group [72]. In this study, two qualitative
and quantitative methods were used to investigate the
content validity. The use of ideas of experts with know-
ledge and experience in the subject matter can signifi-
cantly help to increase the content validity of new tools
[73]. Construct validity can be provided by factor ana-
lysis, testing hypothesis, and convergent and divergent
validity [62], all of which were investigated in the present
study. In the present study, the Meyer-Kaiser-Olkin
(KMO) index was examined before performing the ex-
ploratory factor analysis to examine sampling adequacy.
The amount of KMO = 0.8 indicates that the number of
samples is sufficient [74]. Bartlett’s test of sphericity was
also run to investigate the appropriateness of factor ana-
lysis. The significance of this test means that the correl-
ation matrix between the items is confirmed and the
factor analysis model is appropriate [75]. In the present
study, 360 samples were used in the investigation of ex-
ploratory factor analysis and 200 samples in study of
confirmatory factor analysis. Determining the number of
samples is essential for factor analysis. Costello and Os-
borne (2005) consider the best way to determine sample
size to be the ratio of sample to item. They believe that
it is better to take 10 or 20 samples for each item [76].
According to the obtained results, one of the best fit
indexes of the equations models is the root mean error
of approximation (RMSEA). For models with a good fit,
this value should be less than 0.09 [77]. Given the value
of the RMSEA in the present study, the results indicated
that the model was appropriate. The results of explora-
tory and confirmatory factor analyses showed that E-
RAS has four dimensions, namely, motivation, self-
regulatory, cognition, and emotional-effective. Sockeel
et al. (2006) stated that apathy has four dimensions in-
cluding intellectual curiosity, self-awareness, emotion
and action initiation [30]. The first dimension is motiv-
ation, which explains 15,134% of the total variance. This
dimension addresses issues such as the patient’s motiv-
ation and interests in disease management. Ang et al.
(2017) labelled this dimension as social motivation and
argued that this subscale includes items that examine a
person’s motivation to participate in social interactions
[32]. The second dimension is Self-Regulatory, which ex-
plained 13.174% of the variance. The items of this di-
mension address the patients’ value-based behaviours
and efforts aimed to control the situation. This dimen-
sion was labelled in the study of Levy and Dubois
(2006), quoted by Habib (2004), as auto-activation and
defined as a low desire toward thoughts and related be-
haviours such as lack of motor responsiveness (akinesia)
and lack of discourse [78]. Ang et al. assigned the behav-
ioural activation label to this subscale. Ang argues that
this dimension examines things like self-initiate goal-
directed behaviour (for example, what a person should
do without the need to others’ reminding). However, in
the present study, such variables were assigned to the
motivation dimension. The third dimension is cognition,
that explained 11.940% of the variance in the epilepsy-
Table 7 Convergent and divergent validity, internal consistency, and constructs reliability of E-RAS
Factor α θ Ω CR First-order Second-order
AVE MSV ASV AVE
Motivation 0.770 0.726 0.728 0.883 0.528 0.240 0.177 0.516
Self-Regulatory 0.763 0.759 0.742 0.780 0.550 0.302 0.213
Cognition 0.792 0.803 0.815 0.846 0.531 0.302 0.239
Emotional-Effective 0.889 0.846 0.840 0.912 0.541 0.176 0.145
Abbreviations: E-RAS epilepsy– related apathy scale, a Cronbach’s alpha coefficients, θ theta coefficient, Ω McDonald omega coefficient, CR construct reliability, AVE
average variance extracted, MSV maximum shared squared variance, ASV average shared squared variance
Table 8 ICC, SEM, MDC and MIC of the E-RAS in adult with epilepsy
Factor Range of score ICC(95% CI) P-value SEM MDC MIC Agreement
Motivation 12–28 0.707(0.614–0.853) < 0.001 2.138 5.926 1.472 positive
Self-Regulatory 6–12 0.798(0.696–0.898) < 0.001 .822 2.279 0.287 positive
Cognition 5–20 0.843(0.762–0.903) < 0.001 1.434 3.975 1.813 positive
Emotional-Effective 17–34 0.750(0.684–0.879) < 0.001 2.305 6.389 2.952 positive
Total 45–91 0.843(0.773–0.900) < 0.001 4.567 12.660 5.321 positive
Abbreviations: ICC intra-class correlation, SEM standard error of measurement, MDC Minimal Detectable Change, MIC minimal important change
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related apathy variable in our study. In fact, this dimen-
sion includes the items that address the patient’s inabil-
ity to understand and recognize the disease, its
consequences, and treatment protocol. In their study,
Levy and Dubois (2006) also considered cognition as
one of the dimensions of apathy. According to Levy, this
dimension addresses an individual’s inability to manage
cognitive goals and strategies with a negative impact on
cognitive and action planning [78]. The fourth dimen-
sion is emotional-effective. This dimension was found to
explain 8.102% variance in the epilepsy-related apathy
variable. This dimension measures the patient’s emo-
tional and behavioural reactions in facing others’ reac-
tions to the disease and its symptoms, as well as the
patient’s reaction to the disease and its complications.
This dimension was also found as one of the dimensions
of apathy in the study of Levy and Dubois (2006) [78].
Ang et al. (2017) later labelled this dimension as emo-
tional sensitivity and argued that this subscale included
items that express a person’s positive and negative
emotions, which seem to be similar to emotional
blunting. The results show that epilepsy-related ap-
athy in all four factors had a significant relationship
with the demographic and clinical variables of adult
epileptic patients [32].
The results also showed that there was a positive cor-
relation between the four E-RAS subscales and older
age. Reasonable assumption is that aging can be a factor
for reduced motivation and hope in patients with epi-
lepsy to adopt a new plan for the future, and also de-
creased motivation to adhere to treatment. The results
also showed a positive correlation between E-RAS sub-
scales and long-term administration of antiepileptic
drugs (AEDs). Prolonged use of AEDs appears to cause
fatigue and frustration with the treatment protocol.
Therefore, the patient’s motivation to pursue the goals
of the treatment protocol is reduced. The study of Seo
et al. (2017) also showed that there was a statistically sig-
nificant relationship between the duration of AEDs con-
sumption and apathy [12]. The results of the present
study showed that the rate of epilepsy-related apathy re-
duced with increasing number of seizures in most sub-
scales. Besides that, apathy in females and married
people is less than other groups. It can be argued that
increasing the number of seizures increases the
perception of the threat and increases the patient’s mo-
tivation to adhere to a treatment protocol and increases
setting goals to achieve recovery and to reduce the ef-
fects of the disease. Married people seem to be more
motivated to manage themselves because of their social
support. The results also showed that women had less
apathy than men. This may be due to the characteristics
of women and their sensitivity and paying attention to
various aspects of health, illness and treatment. In exam-
ining the reliability of an instrument, three characteris-
tics, internal consistency, stability, and error
measurement are mainly evaluated [44], all three of
which were measured in the present study. The alpha
coefficient for the whole E-RAS was 0.815. An alpha co-
efficient of 0.7 is often considered as an acceptable
threshold for reliability. However, 0.8 and 0.95 are pre-
ferred for the psychometric quality of scales [79]. To test
the stability in the present study, the test-retest method
was implemented. Stability of an instrument refers to
the repeatability of its administration or its reliability. In
the test-retest, which is the most common method to
test stability, the test is administered twice to one group
with a given time interval. To this end, after a period of
time (usually 2 weeks), the same instrument is adminis-
tered again to the same respondents, and then the cor-
relation between the test and retest scores is calculated
[62]. Efforts were made to make E-RAS items unambigu-
ous and straightforward so that low-literacy participants
could fill out the instrument. Schinka et al. (2013) argue
that instrument items should be unambiguous and
straightforward, and should not contradict religious be-
liefs, ethnicity, race, economic status, or gender [80].
Some E-RAS items are scored inversely. Inversely scored
items have been proposed as a strategy to prevent re-
sponse bias in using self-report instruments. Response
bias refers to a pattern of response that does not reflect
the actual opinions or conditions of the respondents
[81]. Missing values and their management were import-
ant throughout the factor analysis and should be re-
ported [75]. In this study, the missing values were
reported.
Conclusion
The results of the present study showed that E-RAS was
a multidimensional instrument and had acceptable
Table 9 Percentage of people who scored the minimum and maximum scores on each subscale and the entire E-RAS scale
Factor Range of variations Minimum score (%) Maximum score (%)
Motivation 26–10 22.25 57.2
Self-Regulatory 12–3 21.91 54.9
Cognition 20–8 28.16 52.13
Emotional-Effective 30–13 26.35 48
Total 76–48 23.41 53.03
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validity and reliability for the study of epilepsy-related
apathy symptoms in adult epileptic patients. E-RAS is in
fact a measure of motivation and can serve as a valid
predictor of epilepsy recovery. E-RAS may be useful in
diagnosing the patient’s problems in managing the dis-
ease, or it may be used as a guide for families dealing
with functional problems of epileptic patients.
Implications and limitations
 In this study, efforts were made to investigate the
validity of a research instrument through a
psychometric process and by reporting the relevant
details in order to provide appropriate evidence to
ensure its validity.
 In designing E-RAS, it was attempted to reduce the
number of items so that it would not be boring for
patients with epilepsy.
 E-RAS items were modified by experts and patients
with epilepsy throughout various phases to
ultimately achieve an instrument that can be
understood and accepted by samples with different
levels of literacy and sociocultural status.
 Sampling in the qualitative and quantitative phases
were done in different regions of Iran, enabling us to
reduce the effect of the culture variable on samples’
responses.
 In this study, an adequate number of samples were
included so that the results could represent epilepsy-
related apathy in adults.
 Psychological and environmental variables may be
the primary cause of epilepsy. Therefore, the results
of the present study may be influenced by variables
that have not been taken into account in the current
study.
 E-RAS is a self-report instrument and therefore can
lead to report errors.
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